Curis, Inc. (NASDAQ:CRIS)’s share price reached a new 52-week low during trading on Friday . The stock traded as low as $1.22 and last traded at $1.23, with a volume of 3637662 shares trading hands. The stock had previously closed at $1.35.

A number of equities analysts recently issued reports on CRIS shares. Zacks Investment Research lowered Curis from a “hold” rating to a “sell” rating in a report on Friday. BidaskClub raised Curis from a “strong sell” rating to a “sell” rating in a report on Thursday, August 17th. ValuEngine raised Curis from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Finally, Guggenheim started coverage on Curis in a report on Monday, October 23rd. They issued a “buy” rating and a $7.00 price objective for the company. Three equities research analysts have rated the stock with a sell rating and three have given a buy rating to the company. Curis currently has a consensus rating of “Hold” and an average target price of $6.50.

The company has a quick ratio of 3.72, a current ratio of 5.15 and a debt-to-equity ratio of 1.24.

Curis (NASDAQ:CRIS) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). The firm had revenue of $2.44 million for the quarter, compared to the consensus estimate of $2.19 million. Curis had a negative net margin of 629.29% and a negative return on equity of 250.58%. The business’s revenue for the quarter was up 38.6% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.21) earnings per share. analysts anticipate that Curis, Inc. will post -0.4 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. boosted its stake in Curis by 62,201.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,381,798 shares of the biotechnology company’s stock valued at $3,691,000 after purchasing an additional 2,377,975 shares in the last quarter. FNY Partners Fund LP lifted its position in shares of Curis by 350.0% during the 3rd quarter. FNY Partners Fund LP now owns 67,500 shares of the biotechnology company’s stock valued at $100,000 after acquiring an additional 52,500 shares during the last quarter. First Eagle Investment Management LLC lifted its position in shares of Curis by 10.4% during the 3rd quarter. First Eagle Investment Management LLC now owns 26,508,672 shares of the biotechnology company’s stock valued at $39,498,000 after acquiring an additional 2,500,000 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Curis by 8.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 100,023 shares of the biotechnology company’s stock valued at $190,000 after acquiring an additional 8,102 shares during the last quarter. Finally, State Street Corp lifted its position in shares of Curis by 10.4% during the 2nd quarter. State Street Corp now owns 1,857,044 shares of the biotechnology company’s stock valued at $3,511,000 after acquiring an additional 175,424 shares during the last quarter. 44.67% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Curis, Inc. (CRIS) Hits New 1-Year Low at $1.22” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/10/curis-inc-cris-hits-new-1-year-low-at-1-22.html.

Curis Company Profile

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Receive News & Stock Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related stocks with our FREE daily email newsletter.